R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves healthcare providers, including health systems and hospitals, physicians groups, and municipal and private emergency medical service providers, as well as intermountain homecare, hospice and palliative care, and durable medical equipment and infusion therapy business. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Industry, Sector and Symbol
Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
Phone312-324-7820
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$868.50 million
Profitability
Miscellaneous
Employees18,600
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
R1 RCM (NASDAQ:RCM) Frequently Asked Questions
What is R1 RCM's stock symbol?
R1 RCM trades on the NASDAQ under the ticker symbol "RCM."
How were R1 RCM's earnings last quarter?
R1 RCM Inc (NASDAQ:RCM) released its quarterly earnings data on Friday, February, 22nd. The financial services provider reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The financial services provider earned $262.90 million during the quarter, compared to analyst estimates of $264.48 million. R1 RCM had a negative return on equity of 145.94% and a negative net margin of 5.22%. The business's revenue for the quarter was up 87.4% on a year-over-year basis. View R1 RCM's Earnings History.
When is R1 RCM's next earnings date?
What guidance has R1 RCM issued on next quarter's earnings?
R1 RCM issued an update on its FY 2019 earnings guidance on Friday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.15-1.25 billion, compared to the consensus revenue estimate of $1.19 billion.
What price target have analysts set for RCM?
4 equities research analysts have issued 1 year target prices for R1 RCM's shares. Their forecasts range from $10.00 to $20.00. On average, they anticipate R1 RCM's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price. View Analyst Price Targets for R1 RCM.
What is the consensus analysts' recommendation for R1 RCM?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for R1 RCM.
What are Wall Street analysts saying about R1 RCM stock?
Here are some recent quotes from research analysts about R1 RCM stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating on RCM shares and maintain our 12-mo. PT of $13. We recently attended a comprehensive webinar hosted by R1 RCM, titled Intelligent Driving a New Level of Revenue Cycle Performance". During the session, we were provided a background on automation followed by a more detailed view into how R1 is using automation to drive performance for its provider clients. We continue to believe there is significant opportunity for automation to generate value for providers. R1 has an impressive digital offering, which we believe provides a competitive edge. We believe these efforts should drive solid top-line growth and margin expansion long term." (4/12/2019)
- 2. According to Zacks Investment Research, "R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. " (3/2/2019)
Has R1 RCM been receiving favorable news coverage?
Media headlines about RCM stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. R1 RCM earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the financial services provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of R1 RCM's key competitors?
What other stocks do shareholders of R1 RCM own?
Who are R1 RCM's key executives?
R1 RCM's management team includes the folowing people:
- Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 48)
- Mr. Christopher Simon Ricaurte, CFO & Treasurer (Age 59)
- Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 49)
- Mr. Richard B. Evans Jr., Principal Accounting Officer, Sr. VP & Corp. Controller (Age 51)
- Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
Who are R1 RCM's major shareholders?
R1 RCM's stock is owned by a number of of retail and institutional investors. Top institutional investors include P.A.W. Capital Corp (0.36%), Insight Wealth Strategies LLC (0.16%), Tibra Equities Europe Ltd (0.04%) and Bailard Inc. (0.02%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli and Charles J Ditkoff. View Institutional Ownership Trends for R1 RCM.
Which institutional investors are buying R1 RCM stock?
RCM stock was purchased by a variety of institutional investors in the last quarter, including Insight Wealth Strategies LLC, Tibra Equities Europe Ltd, P.A.W. Capital Corp and Bailard Inc.. View Insider Buying and Selling for R1 RCM.
How do I buy shares of R1 RCM?
Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is R1 RCM's stock price today?
One share of RCM stock can currently be purchased for approximately $10.48.
How big of a company is R1 RCM?
R1 RCM has a market capitalization of $1.16 billion and generates $868.50 million in revenue each year. The financial services provider earns $-45,300,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. R1 RCM employs 18,600 workers across the globe.
What is R1 RCM's official website?
How can I contact R1 RCM?
R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The financial services provider can be reached via phone at 312-324-7820 or via email at [email protected]
MarketBeat Community Rating for R1 RCM (NASDAQ RCM)
MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote "Outperform" if you believe RCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
